10th April 2025Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO
29th March 2025Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25
17th March 2025Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25)
30th August 2024Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024
8th April 2024Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24
25th March 2024Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)
12th November 2023Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina
7th November 2023Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
16th August 2023Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
5th June 2023Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
17th May 2023Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect
9th January 2023Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
